Skip to main content
. 2018 Sep 20;103(12):2079–2087. doi: 10.3324/haematol.2018.194118

Figure 4.

Figure 4.

Time to MRD negativity in the ITT population. MRD-negative status was evaluated over time at a sensitivity threshold of 10−5 using bone marrow aspirate samples that were prepared using Ficoll and analyzed by the clonoSEQ® assay. MRD: minimal residual disease; D-Vd: daratumumab plus bortezomib and dexamethasone; Vd: bortezomib and dexamethasone.